150 related articles for article (PubMed ID: 38385640)
1. The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder.
Carollo M; Carollo N; Montan G
CNS Neurosci Ther; 2024 Feb; 30(2):e14653. PubMed ID: 38385640
[No Abstract] [Full Text] [Related]
2. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
[TBL] [Abstract][Full Text] [Related]
3. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
Afshar H; Roohafza H; Mohammad-Beigi H; Haghighi M; Jahangard L; Shokouh P; Sadeghi M; Hafezian H
J Clin Psychopharmacol; 2012 Dec; 32(6):797-803. PubMed ID: 23131885
[TBL] [Abstract][Full Text] [Related]
4. N-Acetylcysteine Augmentation in Children and Adolescents Diagnosed With Treatment-Resistant Obsessive-Compulsive Disorder: Case Series.
Yazici KU; Percinel I
J Clin Psychopharmacol; 2015 Aug; 35(4):486-9. PubMed ID: 26066338
[No Abstract] [Full Text] [Related]
5. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.
Paydary K; Akamaloo A; Ahmadipour A; Pishgar F; Emamzadehfard S; Akhondzadeh S
J Clin Pharm Ther; 2016 Apr; 41(2):214-9. PubMed ID: 26931055
[TBL] [Abstract][Full Text] [Related]
6. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
[TBL] [Abstract][Full Text] [Related]
7. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
[TBL] [Abstract][Full Text] [Related]
9. "N-Acetylcysteine for Obsessive-Compulsive and Related Disorders in Children and Adolescents: A Review".
Parli GM; Gales MA; Gales BJ
Ann Pharmacother; 2023 Jul; 57(7):847-854. PubMed ID: 36384314
[TBL] [Abstract][Full Text] [Related]
10. The role of glutamatergic dysfunction in treatment-resistant obsessive-compulsive disorder: treatment of an adolescent case with N-acetylcysteine augmentation.
Yazici KU; Percinel I
J Child Adolesc Psychopharmacol; 2014 Nov; 24(9):525-7. PubMed ID: 25264963
[No Abstract] [Full Text] [Related]
11. What Future Role Might N-Acetyl-Cysteine Have in the Treatment of Obsessive Compulsive and Grooming Disorders?: A Systematic Review.
Smith L; Tracy DK; Giaroli G
J Clin Psychopharmacol; 2016 Feb; 36(1):57-62. PubMed ID: 26629962
[TBL] [Abstract][Full Text] [Related]
12. Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: A systematic review of the clinical evidence.
Couto JP; Moreira R
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():245-254. PubMed ID: 29908912
[TBL] [Abstract][Full Text] [Related]
13. Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder.
Corregiari FM; Bernik M; Cordeiro Q; Vallada H
Clinics (Sao Paulo); 2012; 67(4):335-40. PubMed ID: 22522758
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Weiss EL; Potenza MN; McDougle CJ; Epperson CN
J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
[TBL] [Abstract][Full Text] [Related]
15. Obsessive-compulsive disorder in Tourette syndrome.
Goodman WK; Storch EA; Geffken GR; Murphy TK
J Child Neurol; 2006 Aug; 21(8):704-14. PubMed ID: 16970872
[TBL] [Abstract][Full Text] [Related]
16. Selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Drug Ther Bull; 1995 Jun; 33(6):47-8. PubMed ID: 7587998
[No Abstract] [Full Text] [Related]
17. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
[TBL] [Abstract][Full Text] [Related]
18. Glutamatergic dysfunction in skin-picking disorder: treatment of a pediatric patient with N-acetylcysteine.
Percinel I; Yazici KU
J Clin Psychopharmacol; 2014 Dec; 34(6):772-4. PubMed ID: 25203471
[No Abstract] [Full Text] [Related]
19. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors.
Vythilingum B; Cartwright C; Hollander E
Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S7-13. PubMed ID: 11110014
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of obsessive-compulsive disorder in an adult].
Kähkönen S; Holmberg N
Duodecim; 2010; 126(11):1310-6. PubMed ID: 20681354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
